Cancer’s been ducking punches for decades, slipping past chemo, sidestepping immunotherapy, always changing form like it’s got a backstage pass to evolution. But every long fight has that one moment when the tide shifts. That moment just showed up wearing a lab coat in San Diego, courtesy of Onchilles Pharma. Founded in 2018 by Court R. Turner, J.D., and Dr. Lev Becker, Ph.D., Onchilles isn’t chasing another checkpoint or signaling cascade, it’s weaponizing the body’s own immune system through something called the ELANE pathway, a biological ambush Becker uncovered at the University of Chicago. ELANE turns neutrophils, the body’s first responders, into assassins that find, infiltrate, and eliminate cancer cells while sparing healthy ones.
Onchilles locked in a $25M Series A1 round that feels more like a strategic alignment than a cash grab. Invivium Capital, Kennedy Lewis Investment Management, and UCM Ventures joined as new investors, while LYZZ Capital Advisors and Lincoln Park Capital Fund doubled down as returning believers. Together, they push Onchilles’ total Series A to $32M, with cumulative funding now sitting at roughly $40M. On the board, you’ll find some serious horsepower: Kevin Li, Ph.D. (LYZZ), Mike Liang, Ph.D. (Invivium), and Thomas DeSouza (Kennedy Lewis), each backing a science that’s equal parts elegance and precision.
The data isn’t hype, it’s hard proof. Onchilles has run N17350, its lead candidate, across 11 cancer types, 80+ cell lines, 41 patient samples, and 25+ animal models. The results? Selective tumor kill, immune activation, durable remissions, and no resistance even after repeat dosing. More impressive, the company’s already completed a GMP manufacturing run, over 5,000 doses ready for human use. Trials kick off in Australia in early 2026, with U.S. IND clearance and enrollment expected mid-year. That’s not a timeline, it’s a countdown.
Guiding the ship, Court R. Turner brings more than 25 years of biotech grit, from Avalon Ventures to building Synthorx (acquired by Sanofi). Dr. Lev Becker, now full-time CSO, transforms lab discovery into clinical reality. Alongside veterans like Marc Nasoff, Ph.D., and Emily Roberts-Thomson, this lean team is marching toward clinical proof-of-concept by late 2026.
In a market forecasted to hit $600.97B by 2034, growing at 11.54% CAGR, Onchilles isn’t just in the fight, it’s changing the fight’s physics. The ELANE pathway isn’t about killing faster; it’s about killing smarter. And for cancer, that’s a problem money can’t outrun.
